{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PsA+%28Psoriatic+Arthritis%29&page=3", "query": { "condition": "PsA (Psoriatic Arthritis)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 55, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PsA+%28Psoriatic+Arthritis%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PsA+%28Psoriatic+Arthritis%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T08:52:52.453Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06506916", "title": "A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Plaque Psoriasis", "Psoriatic Arthritis" ], "interventions": [ { "name": "bimekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2024-07-29", "completion_date": "2028-03-14", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-08T08:52:52.453Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Tampa, Florida + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06506916" }, { "nct_id": "NCT04163016", "title": "A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis", "Psoriatic Arthritis", "Crohn's Disease", "Axial Spondyloarthritis", "Plaque Psoriasis" ], "interventions": [ { "name": "Pharmacokinetics of certolizumab pegol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 22, "start_date": "2020-06-19", "completion_date": "2023-05-23", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-08T08:52:52.453Z", "location_count": 3, "location_summary": "Minneapolis, Minnesota • Durham, North Carolina • Oklahoma City, Oklahoma", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04163016" }, { "nct_id": "NCT02798211", "title": "Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Secukinumab 300 mg", "type": "DRUG" }, { "name": "Secukinumab 150 mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 258, "start_date": "2016-06-27", "completion_date": "2018-12-05", "has_results": true, "last_update_posted_date": "2021-10-07", "last_synced_at": "2026-10-08T08:52:52.453Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "El Cajon", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02798211" }, { "nct_id": "NCT05669833", "title": "Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Guselkumab", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 63, "start_date": "2023-07-14", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-10-08T08:52:52.453Z", "location_count": 14, "location_summary": "Loxahatchee Groves, Florida • Plant City, Florida • Riverview, Florida + 11 more", "locations": [ { "city": "Loxahatchee Groves", "state": "Florida" }, { "city": "Plant City", "state": "Florida" }, { "city": "Riverview", "state": "Florida" }, { "city": "Lilburn", "state": "Georgia" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05669833" }, { "nct_id": "NCT03671148", "title": "A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis (PsA)" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Risankizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2019-03-07", "completion_date": "2026-06-04", "has_results": true, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-08T08:52:52.453Z", "location_count": 55, "location_summary": "Anniston, Alabama • Fullerton, California • Huntington Beach, California + 50 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Fullerton", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Palma", "state": "California" }, { "city": "San Leandro", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03671148" }, { "nct_id": "NCT05623345", "title": "Psoriatic Arthritis Study of Izokibep", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Izokibep", "type": "DRUG" }, { "name": "Placebo to izokibep", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ACELYRIN Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 351, "start_date": "2022-11-21", "completion_date": "2024-08-08", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-10-08T08:52:52.453Z", "location_count": 40, "location_summary": "Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05623345" }, { "nct_id": "NCT03347110", "title": "A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2017-11-22", "completion_date": "2020-10-29", "has_results": true, "last_update_posted_date": "2023-12-01", "last_synced_at": "2026-10-08T08:52:52.453Z", "location_count": 11, "location_summary": "Lexington, Kentucky • Hagerstown, Maryland • Lansing, Michigan + 8 more", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "Hagerstown", "state": "Maryland" }, { "city": "Lansing", "state": "Michigan" }, { "city": "Rochester", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03347110" }, { "nct_id": "NCT06004700", "title": "Improving Virtual Care of Arthritis: Integrating a Smartphone App Into the EHR for Improved Timeliness of Visits", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Arthritis", "Psoriatic Arthritis" ], "interventions": [ { "name": "Mobile Application", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 278, "start_date": "2024-04-11", "completion_date": "2026-10-01", "has_results": false, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-10-08T08:52:52.453Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06004700" }, { "nct_id": "NCT03104400", "title": "A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo to Upadacitinib", "type": "DRUG" }, { "name": "Placebo to Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1705, "start_date": "2017-04-27", "completion_date": "2024-09-09", "has_results": true, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-10-08T08:52:52.453Z", "location_count": 114, "location_summary": "Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 100 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03104400" }, { "nct_id": "NCT02413749", "title": "DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Psoriatic Arthritis" ], "interventions": [], "intervention_types": [], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 68, "start_date": "2015-04-13", "completion_date": "2016-12-28", "has_results": false, "last_update_posted_date": "2017-08-18", "last_synced_at": "2026-10-08T08:52:52.453Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02413749" } ] }